← Back to Clinical Trials
Recruiting NCT06998888

NCT06998888 Determining the Effectiveness of Remote Monitoring of Cancer Patients With Oral Cancer Treatment Using Caaring® Software

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06998888
Status Recruiting
Phase
Sponsor Persei Vivarium
Condition Cancer
Study Type INTERVENTIONAL
Enrollment 194 participants
Start Date 2025-04-11
Primary Completion 2025-07

Trial Parameters

Condition Cancer
Sponsor Persei Vivarium
Study Type INTERVENTIONAL
Phase N/A
Enrollment 194
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2025-04-11
Completion 2025-07
Interventions
software Caaring (remote monitoring app)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The goal of this clinical trial investigation with device is to determinate the efficacy of the remote monitoring in cancer patients with a software called Caaring® a través del cumplimento terapéutico y de dosis. The main question it aims to answer is if the development of a self-management platform (Caaring®) empowers cancer patients throughout their illness, reducing the number of in-person and telephone visits assisted by specialized medical and nursing staff. For this, researchers will compare the assessments between the two groups. This is a randomized study with two arms. Online telemonitoring group: The follow-up of these patients will be carried out prospectively remotely through the Caaring® platform. And Prospective Control group: The data of these patients are collected prospectively for their routine medical visits for 12 weeks after their inclusion. Caaring group patients must have sufficient technological skills to use a smartphone.

Eligibility Criteria

Inclusion Criteria: * Patients who provide informed consent. * Age ≥18 years. * Oncology patients undergoing active outpatient oral therapy with: capecitabine, cyclin inhibitors, hormonal therapies, TKI inhibitors, monotherapy with or without intravenous therapy. * Oncology patients undergoing active outpatient oral oncology treatment expected within 12 weeks of inclusion. * Patients who must demonstrate sufficient technological skills to operate a smartphone through the "technological skills questionnaire." * Patients who do not meet the exclusion criteria. Exclusion Criteria: * Patients with cognitive or sensory difficulties or insufficient command of Spanish language that, in the opinion of the healthcare professional conducting the recruitment, makes it difficult to understand the questions posed in the surveys, scales, or instruments used in the study, provided they do not have a legal representative capable of participating in the study. * Patients for whom it is anticipated that

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology